CTLA4 and neoplasm: CTLA-4 is a negative regulator of Treg cell homeostasis and their cell proliferation (54), and anti-CTLA-4 treatment in tumor models enhances the Treg cell population even though it yields tumor-specific immune responses (55), opposing their therapeutic outcomes in tumor studies.